Who
Marcia Belvin
SVP, Chief Scientific Officer
Company insider
Files Form 4 as: SVP, Chief Scientific Officer, CytomX Therapeutics.
In numbers
- Trades disclosed
- 33
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $496K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 22 Mar 2023
- Last trade
- 17 Mar 2026
- Last filed
- 19 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Mar 2026filed 19 Mar 2026 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Sold | $202K31,492 at $6.42 | filing |
| 17 Mar 2026filed 19 Mar 2026 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Sold | $202K31,492 at $6.42 | filing |
| 2 Feb 2026filed 4 Feb 2026 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 26 Sep 2025filed 30 Sep 2025 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,300 at $0.00 | filing |
| 26 Sep 2025filed 30 Sep 2025 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,150 at $0.00 | filing |
| 16 Jun 2025filed 17 Jun 2025 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Sold | $37K13,884 at $2.69 | filing |
| 13 Jun 2025filed 17 Jun 2025 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —37,500 at $0.00 | filing |
| 13 Jun 2025filed 17 Jun 2025 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Code M | —37,500 at $0.00 | filing |
| 18 Mar 2025filed 20 Mar 2025 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Sold | $12K19,512 at $0.60 | filing |
| 4 Feb 2025filed 10 Feb 2025 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 4 Feb 2025filed 10 Feb 2025 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 4 Feb 2025filed 10 Feb 2025 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 4 Feb 2025filed 10 Feb 2025 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Code A | —57,500 at $0.00 | filing |
| 4 Feb 2025filed 6 Feb 2025 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 4 Feb 2025filed 6 Feb 2025 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 4 Feb 2025filed 6 Feb 2025 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 4 Feb 2025filed 6 Feb 2025 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Code A | —57,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.